Black Diamond Therapeutic... (BDTX)
Black Diamond Therapeutics Statistics
Share Statistics
Black Diamond Therapeutics has 56.66M shares outstanding. The number of shares has increased by 0.73% in one year.
| Shares Outstanding | 56.66M |
| Shares Change (YoY) | 0.73% |
| Shares Change (QoQ) | 0.14% |
| Owned by Institutions (%) | 84.78% |
| Shares Floating | 43.15M |
| Failed to Deliver (FTD) Shares | 4.04K |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 10.17M, so 17.96% of the outstanding shares have been sold short.
| Short Interest | 10.17M |
| Short % of Shares Out | 17.96% |
| Short % of Float | 30.19% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -1.69 and the forward PE ratio is -1.17. Black Diamond Therapeutics's PEG ratio is 0.05.
| PE Ratio | -1.69 |
| Forward PE | -1.17 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 1.41 |
| P/FCF Ratio | -1.89 |
| PEG Ratio | 0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Black Diamond Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.92, with a Debt / Equity ratio of 0.23.
| Current Ratio | 4.92 |
| Quick Ratio | 4.92 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | -0.24 |
| Debt / FCF | -0.3 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.9M |
| Employee Count | 24 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -68.77% in the last 52 weeks. The beta is 2.82, so Black Diamond Therapeutics's price volatility has been higher than the market average.
| Beta | 2.82 |
| 52-Week Price Change | -68.77% |
| 50-Day Moving Average | 1.76 |
| 200-Day Moving Average | 3.31 |
| Relative Strength Index (RSI) | 51.12 |
| Average Volume (20 Days) | 3.26M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -78.78M |
| Net Income | -69.68M |
| EBITDA | -78.78M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.27 |
Balance Sheet
The company has 36.44M in cash and 18.78M in debt, giving a net cash position of 17.66M.
| Cash & Cash Equivalents | 36.44M |
| Total Debt | 18.78M |
| Net Cash | 17.66M |
| Retained Earnings | -487.11M |
| Total Assets | 122.64M |
| Working Capital | 80.6M |
Cash Flow
In the last 12 months, operating cash flow was -62.3M and capital expenditures 0, giving a free cash flow of -62.3M.
| Operating Cash Flow | -62.3M |
| Capital Expenditures | 0 |
| Free Cash Flow | -62.3M |
| FCF Per Share | -1.13 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BDTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BDTX is $15, which is 849.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 849.4% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -5.54 |
| Piotroski F-Score | 1 |